Kilitch Drugs (India): The financial results for the period ended September 30, 2026

What happened

Kilitch Drugs (India) (KILITCH) filed a disclosure with the exchanges on 6 November 2026 at 08:49 PM titled "The financial results for the period ended September 30, 2026".

Company snapshot

Kilitch Drugs (India) is a micro-cap company, with a market value of about ₹730 crore.

The stock last traded at ₹208.9, against a 52-week range of ₹117.3–₹267.9 (22.0% below the high).

Before this filing the shares had moved −10.6% over the month and +9.8% over three months. Average daily turnover over the last 20 sessions was about ₹1.56 crore.

Promoters held 63.77% at the end of Q1 FY27. Foreign institutions owned 0.12% and domestic institutions 0.00%.

What history shows

This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.

Market-wide, 10,949 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.
• 6 November 2026: Board meeting — Financial Results.

In the news

Recent coverage elsewhere (links open the original publisher):

• Kilitch Drugs to divest Ethiopian arm for $14 million — The Hindu, 24 Oct 2026
• Kilitch Drugs divests Ethiopian arm for $14 million to fund mfg expansion — pharma.economictimes.indiatimes.com, 24 Oct 2026
• Kilitch Drugs (India) Ltd. Financials – Balance Sheet, Profit & Loss, Cash Flow — Value Research, 4 Nov 2026
• Kilitch Drugs (India) Limited (KILITCH.NS) Seasonal Returns Chart — Yahoo! Finance Canada, 30 Oct 2026
• Kilitch Drugs (India) Ltd. Key Financial Ratios – Valuation, Profitability & More — Value Research, 4 Nov 2026

Source

• Exchange filing (PDF)